Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
Key Highlights
- ➤Quest Diagnostics and Waters collaboration expands at-home HPV screening nationwide in 2027
- ➤Onclarity Self-Collection Kit reaches Quest clinician, health plan, consumer channels
- ➤Quest’s network includes over 2,000 patient service centers nationwide
- ➤BD Onclarity HPV Assay supports all ASCCP Enduring Risk-Based Management Guidelines
Expert Statements
Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation
“In the U.S., there are over 24 million un- and under-screened individuals and approximately 14,000 new cases of cervical cancer each year”
Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation
“By bringing together Waters' diagnostic innovation with Quest's national reach and capabilities, we have an opportunity to make a meaningful impact for these millions of individuals who remain at risk, advancing our shared goal of eliminating this highly preventable disease.”
Damian ("Pat") Alagia, M.D., Senior Medical Director, Women's & Reproductive Health, Quest Diagnostics
“Many women struggle to participate in traditional cervical cancer screening methods, primarily due to geographic, socioeconomic, and logistical barriers.”
Damian ("Pat") Alagia, M.D., Senior Medical Director, Women's & Reproductive Health, Quest Diagnostics
“We believe in making healthcare more proactive, personal, and connected for all patients, including through transformational options like at-home self-collection to help fill critical gaps in access to care.”
Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option PR Newswire
* Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 * First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping * Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J., Oct. 20, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a collaboration intended to broaden access to clinically appropriate at-home cervical cancer screening through the FDA-cleared Onclarity™ Self-Collection Kit.(1,2,13)
Get started
Create a free account to read the full story.